News | Prostate Cancer | October 16, 2019

GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent

Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment

GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent

October 16, 2019 — GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging agent. Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations and, as and when approval is received, all subsequent commercial and distribution activities.

Today, prostate cancer is the fourth largest cancer type, accounting for just over 1.2 million new cases and over 350,000 fatalities around the globe in 2018. The diagnostic workflow for detecting prostate cancer starts through a blood test or biopsy, after which patients are typically referred for PET/CT imaging so that radiologists can see their tumor, lymph nodes and any metastasis in order to decide the appropriate course of treatment. The ‘heatmap’ style image enabled by the new tracer shows the precise location and intensity of PSMA, which is expressed on the surface of prostate cancer cells.

Theragnostics has reported data from a phase two clinical study which met its primary and secondary endpoints, demonstrating that one third of newly diagnosed prostate cancer patients — and more than 50 percent of patients with biochemically recurrent disease — had their treatment plans modified as a result of a GalliProst scan. The change in patient management increased to 75 percent in a post-radical radiotherapy setting.

This marks the second agreement between Theragnostics and GE Healthcare, following an agreement in 2018 for a diagnostic tracer for imaging kidney function and scarring. 

For more information: www.gehealthcare.com, www.theragnostics.com

Related Content

Infinitt PACS 7.0 is a faster, more powerful viewer that was built from the ground up to support AI for image analysis and for operational/ workflow improvements in radiology
News | PACS | November 19, 2019
November 19, 2019 — Infinitt North America will be highlighting a next generation,...
 LifeImage Baystate
News | Artificial Intelligence | November 18, 2019
November 18, 2019 — Baystate Health, the premier integrated health syst
News | Artificial Intelligence | November 18, 2019
November 18, 2019 — Visage Imaging, Inc. (Visage), a wholly owned subsidi
RamSoft has been a proponent of the cloud since over a decade; the reason – patient data protection
News | Information Technology | November 18, 2019
November 18, 2019 — A recent report by security firm Emsisoft stated that
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
Image by Pexels from Pixabay RSNA 2019

Image by Pexels from Pixabay 

News | RSNA | November 15, 2019
November 15, 2019 – The 105th Scientific Assembly and Annual Meeting of the...
62-year-old woman with pure ground-glass nodules (GGN). PET/CT fusion image shows pure GGN with tumor maximum standardized uptake value of 2.8 (circle).

62-year-old woman with pure ground-glass nodules (GGN). PET/CT fusion image shows pure GGN with tumor maximum standardized uptake value of 2.8 (circle).

News | PET-CT | November 15, 2019
November 15, 2019 — According to an article published ahead-of-print in the...

Guerbet presented its Contrast&Care injection management solution at ECR 2018

News | Contrast Media | November 13, 2019
November 13, 2019 – Guerbet, a global specialist in...